Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: Muizz M. Kheraj who wrote (5774)	3/3/1998 4:48:00 PM
From: John J H Kim	Respond to of 23519

It doesn't really matter at this point does it? Don't mean to sound abrupt, but the key word here is competition. PFE is the 900# gorilla that's waiting in the jungle to come stomping. Any other smaller new competitor just makes the pieces of the pie smaller. What do the boys in Wall Street think of all this so far? Take a look at the stock chart. They had some hopes, but for now they changed their minds. Things may look better in the future as word gets around as to which products does a better job, and that also will be told by the tape.

To: Muizz M. Kheraj who wrote (5774)	3/4/1998 5:11:00 PM
From: BDR	Respond to of 23519

Imagyn is a new company, I believe, but the ED product it sells, the Erecaid, is old, having been around for at least ten years. It was sold by the Osbon Company, the product was developed by a fellow named Osbon, and there are several imitators on the market. Imagyn bought Osbon, I think, and they market a number of other products primarily directed to GYNs. The only new news in the release was that the Erecaid will be available over the counter. It has never represented a large segment of the ED market but having it available without prescription will help.